3 July 2023 - CMS grants Fresenius Kabi permanent, product-specific Q Code for Idacio (adalimumab-aacf).

Fresenius Kabi announced today the immediate availability in the US of its citrate free adalimumab biosimilar Idacio (adalimumab-aacf) for use in the treatment of chronic auto-immune diseases for all eligible indications of the reference product, Humira (adalimumab).

Read Fresenius Kabi press release